UK markets close in 7 hours 11 minutes

  • FTSE 100

    6,899.74
    +9.25 (+0.13%)
     

  • FTSE 250

    22,272.55
    +4.09 (+0.02%)
     

  • AIM

    1,245.37
    -0.24 (-0.02%)
     

  • GBP/EUR

    1.1532
    +0.0030 (+0.26%)
     

  • GBP/USD

    1.3799
    +0.0047 (+0.34%)
     

  • BTC-GBP

    46,831.95
    +2,576.83 (+5.82%)
     

  • CMC Crypto 200

    1,397.29
    +103.30 (+7.98%)
     

  • S&P 500

    4,141.59
    +13.60 (+0.33%)
     

  • DOW

    33,677.27
    -68.13 (-0.20%)
     

  • CRUDE OIL

    61.02
    +0.84 (+1.40%)
     

  • GOLD FUTURES

    1,745.60
    -2.00 (-0.11%)
     

  • NIKKEI 225

    29,620.99
    +82.29 (+0.28%)
     

  • HANG SENG

    28,855.83
    +358.58 (+1.26%)
     

  • DAX

    15,227.17
    -7.19 (-0.05%)
     

  • CAC 40

    6,202.57
    +18.47 (+0.30%)
     
Careers:

We need to stop confusing home-working with days off

During the pandemic, remote workers are spending longer at their desks than before

BWA Group PLC - Issue of Equity and Director / PDMR Shareholdings

·3-min read

7 April 2021

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF REGULATION 11 OF THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS 2019/310.

BWA Group PLC
(“BWA” or “the Company”)

Issue of Equity and Director / PDMR Shareholdings

BWA Group plc [AQSE: BWAP], which has mineral exploration licences split between Canada and Cameroon at various stages of development and is quoted on London’s AQSE Growth Market (formerly NEX), announces that it has allotted a total of 2,250,000 ordinary shares of 0.5 pence each in the Company ("Ordinary Shares"), at a price of 0.6 pence per share, in part settlement of fees due to current Directors in respect of the quarter ended 31 March 2021.

Application will be made for the Ordinary Shares to be admitted to trading on the AQSE Growth Market and admission is expected to become effective on 12 April 2021.

Following this issue, the Directors' interests in the enlarged issued share capital of the Company are as follows:

Director

Number of Ordinary
Shares allotted

Resulting Ordinary
Shares held

Resulting % of Ordinary Shares held

Richard Battersby

750,000

50,243,906

16.25

Alex Borrelli

375,000

28,866,561

9.34

James Butterfield

750,000

48,919,739

15.83

James Hogg

375,000

1,175,001

0.38

Total Voting Rights

The Company now has 309,112,891 Ordinary Shares in issue, each share carrying the right to one vote. The Company does not hold any Ordinary Shares in Treasury. The figure of 309,112,891 Ordinary Shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

The Company also has £301,000 of 14% Convertible Unsecured Loan Notes 2021 in issue ("CLNS"), convertible into a maximum of 80,803,924 Ordinary Shares if the CLNS have not been redeemed by 31 December 2021.

The Directors of BWA are responsible for the contents of this announcement.

Ends -

For further information:

BWA Group PLC
Richard Battersby
Chairman

+44 (0)7836 238172
enquiries@bwagroupplc.com

Allenby Capital Limited
Corporate Adviser
Nick Harriss

+44 207 3328 5656

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

Details of the persons discharging managerial responsibilities / persons closely associated

Name

Richard Battersby

Alex Borrelli

James Butterfield

James Hogg

Reason for notification

Director of BWA Group plc

Director of BWA Group plc

Director of BWA Group plc

Director of BWA Group plc

Initial

Initial

Initial

Initial

Details of the issuer, emission allowance market participant, auction
platform, auctioneer, or auction monitor

BWA Group plc

BWA Group plc

BWA Group plc

BWA Group plc

LEI

213800XG3K7PTAAG8630

213800XG3K7PTAAG8630

213800XG3K7PTAAG8630

213800XG3K7PTAAG8630

Description of the financial instrument, type of instrument

Ordinary shares of 0.5p each

Ordinary shares of 0.5p each

Ordinary shares of 0.5p each

Ordinary shares of 0.5p each

Identification code

ISIN: GB0033877555

ISIN: GB0033877555

ISIN: GB0033877555

ISIN: GB0033877555

Nature of the transaction

Allotment of Ordinary Shares in part settlement of remuneration

Allotment of Ordinary Shares in part settlement of remuneration

Allotment of Ordinary Shares in part settlement of remuneration

Allotment of Ordinary Shares in part settlement of remuneration

Price(s) and
volume(s)

750,000
Ordinary Shares at 0.6p per share

375,000 Ordinary Shares at 0.6p per share

750,000
Ordinary Shares at 0.6p per share

375,000 Ordinary Shares at 0.6p per share

Aggregated information
Aggregated volume
Price

N/A

N/A

N/A

N/A

Date of the transaction

6 April 2021

6 April 2021

6 April 2021

6 April 2021

Place of the transaction

N/A

N/A

N/A

N/A

Ends -

Latest stories

  • Peru’s presidential runoff pits far-left teacher against rightwing populist

    Far-left labor unionist Pedro Castillo and rightwing populist Keiko Fujimori will square off in a second round of presidential elections that analysts say threatens to further polarize crisis-weary Peru. With 96 percent of ballots counted by Tuesday, schoolteacher Castillo led with 19.09 percent while corruption-accused Fujimori -- daughter of jailed ex-president Alberto Fujimori, followed with 13.35 percent.The pair beat out 16 other candidates in a fragmented first voting round Sunday, and will face each other again for the runoff on June 6.In a country battered by the coronavirus epidemic, a steep economic downturn and years of political upheaval, no single candidate was able to fire up voters to obtain the 51 percent required for victory in the first round.The election happened in Peru's worst week of the coronavirus pandemic -- the day after the country reported a record 384 deaths in 24 hours.As some of the 25 million eligible voters lined up to cast their ballot -- which is mandatory in Peru -- others queued for oxygen refills for ill relatives battling Covid-19.Many said they turned out, despite fear of infection, merely to avoid the fine of 88 soles (about $24) for not voting.Choice 'between dengue and Covid-19'The scene has been set for a fierce battle of economic ideology between left and right in the second round. Castillo, whom opinion polls had not even placed in the top five, represents the far-left Free Peru party, and advocates for state intervention in the economy, including through nationalization of assets.Fujimori, for her part, leads the Popular Force in defending a free-market economy as outlined in Peru's constitution, promulgated under her father's rule in 1993.Both candidates are socially conservative -- opposed to abortion and gay marriage.And both will likely inspire a strong anti-vote.There is deep-seated mistrust of communism in one sector of Peruvian society in light of the long civil war against the Maoist Shining Path group, and strong anti-Fujimorist sentiment in another given the ex-president's poor record on human rights and corruption, and accusations of graft and political manipulation against his heir."Both candidates arouse great antipathy in the population," said political analyst Augusto Alvarez Rodrich."People have reservations about both, but democracy requires that one of them must be chosen, which puts Peruvians at a crossroads. Opting for one (or the other) seems like a choice between dengue and Covid-19," said Rodrich.Rich vs poorCastillo, 51, was a virtual unknown until 2017, when he led thousands of teachers in a protracted national strike that resulted in government compromise.He has made campaign promises to eject "illegal foreigners" who commit crimes, bring back the death penalty, and have the government take control of Peru's energy and mineral resources.Amid the vote count, he declared of his rivalry with Fujimori: "This is a competition between the rich and the poor... also a struggle between the boss and the pawn, and between the master and the slave."Fujimori, 45, is taking her third shot at the presidency, but faces charges for allegedly taking money from scandal-tainted Brazilian construction giant Odebrecht to fund her presidential bids in 2011 and 2016.If she wins in June, the charges will be suspended until after her term as Peruvian law which exempts sitting presidents from prosecution.Recession and upheavalFirst on the new president's agenda will be dealing with the coronavirus, which has killed more than 55,200 in the country of 33 million people.The economy will also require urgent attention.Peru has been in recession since the second quarter of last year after coronavirus lockdowns shuttered businesses and crippled the all-important tourism sector.Its economy contracted more than 11 percent in 2020, four million people lost their jobs and another five million dropped into poverty.To make matters worse, the uncertain electoral outcome worried the markets and saw the Peruvian sol plunge to a record low 3.8 to the US dollar last month.The country has also been convulsed by political upheaval driven by claims of corruption at the highest echelons.Whoever is sworn in on July 28 will be Peru's fifth president in three years, after three fell within days of each other in November 2020 amid protests that left two people dead and hundreds injured.The vote count is all but concluded, but the final two candidates will only officially be announced by the National Jury of Elections in early May.Counting in Sunday's vote for 130 members of Congress will take longer, but is led by Castillo's and Fujimori's parties.(AFP)

  • Trevor Noah Questions How Pausing J&J Shot Will Affect Vaccine Hesitancy

    "It's a setback for a country that's already dealing with a sh*t-ton of vaccine hesitancy," the "Daily Show" host said.

  • China's environmental data: The world's biggest polluter in numbers

    US envoy John Kerry will visit China this week for climate change talks -- the first official trip under the Biden administration -- in a trip Washington hopes will put aside diplomatic spats and focus on joint environment challenges.

  • New Hires to Boost RegTech Provider Napier’s Global Growth Activity

    Fast growing RegTech company, Napier, which provides next-generation anti-money laundering (AML) solutions, has bolstered its senior management team with the appointments of new Global Human Resources Director, Lila Boyce, and EMEA Head of Sales, Roy Williamson.

  • How the 'entitlement gap' is holding women back at work

    The entitlement gap is when men have a greater sense of entitlement to career markers such as promotions, pay-rises and big projects.

  • Civil groups want EU lawmakers to boost privacy rights in planned WhatsApp, Skype rules

    Amnesty International, Privacy International and 28 other civil and human rights groups on Wednesday urged EU lawmakers to take a strong stand on privacy rights in proposed rules governing Facebook's WhatsApp and Microsoft's Skype. The call by the group in a letter to the European Parliament, whose members are spread out across Europe, is in response to what they said are attempts by EU countries to weaken privacy rights. EU countries in February agreed to a joint position in forthcoming negotiations with EU lawmakers and the European Commission on an ePrivacy Regulation that would subject WhatsApp and Skype to the same rules as telecoms providers and restrict the tracking of users in order to provide personalised ads.

  • Global Clinical Genomics Markets Report 2021: Mergers, Acquisitions, and Partnerships Accelerate Adoption of Clinical Genomics

    Dublin, April 14, 2021 (GLOBE NEWSWIRE) -- The "Clinical Genomics Report: The Interplay Between Clinical Research & Clinical Diagnostics" report has been added to ResearchAndMarkets.com's offering. This "Clinical Genomics Report: The Interplay Between Clinical Research and Clinic Diagnostics" provides an in-depth analysis of differences in product characteristics related to data processing, analysis, knowledge extraction and reporting of findings (including the type of content integrated for meaningful extraction), and compliance and security mechanisms. Both clinical end-users and commercial companies who require insight into this expanding industry and its providers and products will benefit from the critical, investigative, and qualitative report. This new, qualitative report provides an in-depth analysis across the complex, multi-step clinical genomics data process (which includes genomic data generation, data flow, and data warehousing), clinical genomics data solution providers, market trends, technologies impacting clinical genomics applications development, clinical genomics adoption challenges, and detailed challenges & needs analysis as identified in discussions with clinical end-users. The report is unique, in that it is not a predictive market research report, but rather builds on data gathered from many end-user interviews combined with an extensive analysis of the clinical genomics sector. Report Contents: Leading medical organizations have established precision medicine programs that support personalized patient treatment. Implementation of clinical genomics applications and enterprise-wide clinical data warehouses are considered the foundation for successful genomic medicine programs. Innovative technological advancements have allowed us to sequence and uncover mutational events at an unprecedented scale while facilitating linking genomic data to high-quality clinical data and diagnosis. Medical organizations understand the benefit of being empowered by data-driven approaches to reduce operational costs and time and to provide researchers and clinicians what is necessary to decipher critical research data and data for clinical decision making. However, technical and scientific limitations still need to be addressed for optimized and universal use of various data sources for both clinical and research purposes. While data production is no longer a challenge, and targeted panels - and to some extent, whole-exome sequencing - are well adopted, the expected dramatic rise in whole-genome sequencing will result in unforeseeable quantities of data at the clinical level that needs to be managed, understood, and communicated. Low-cost sequencing of whole genomes at population scale is already in existence, but not yet widespread in the clinic, as many observed changes at the genome level cannot yet be fully interpreted or explain an existing phenotype. Scalable, fully automated analysis and knowledge extraction solutions incorporating rich annotation information are necessary to overcome these challenges. With massive quantities of NGS data (linked to different clinical and other types of data), artificial intelligence and machine learning are hailed as pivotal solutions to address the data interpretation and knowledge extraction challenges and to advance the clinical application of genomics. Despite increasing efforts and investments in implementing clinical applications and building data solutions, many organizations are still challenged with the multi-faceted complexities in transforming to become data-driven. Implementations are challenged by ineffective data sharing, scalability and automation issues, non-optimized data generation and data flow approaches and non-standardized data from numerous sources. Implementing a complex clinical data warehouse presents many challenges starting with the various data sources it needs to support and the tools required to view the clinical information. Ingestion of data of different types and origins with relevant metadata; data transformation, standardization, and cleansing to support the needs of a diverse set of end-users in both the clinical and research settings; and varied end-users with individual needs and computation capabilities are all important considerations. Clinical interviews detailed challenges associated with creating a workflow that incorporates a clinical data warehouse connecting clinical research with clinical diagnostics and vice versa. This important workflow leads to efficient clinical decision-making and reporting findings between clinical research and the clinic, which can optimize clinical outcomes and patient treatment. Key Topics Covered: 1. THE CLINICAL DIAGNOSTICS & MOLECULAR PROFILING WORKFLOW Clinical Genomics Workflow End Users/PersonasMapping End Users to the Clinical Genomics WorkflowClinical Information Delivery 2. THE PRECISION MEDICINE VALUE CHAIN 3. LEADING MEDICAL ORGANIZATIONS PLATFORM AND INFRASTRUCTURE PREFERENCES IN SUPPORT OF THEIR CLINICAL GENOMICS WORKFLOWS Implementations and Choices of Molecular Profiling and Genetic Testing ProcessesMedical Organizations' Clinical Genetic Testing LabsTesting Lab Selection CriteriaPlatforms and Infrastructures Currently Implemented at Leading Medical OrganizationsAdoption of Commercial and Internally Developed Platforms, Tools, and ServicesMedical Organizations Platform and Infrastructure PreferencesProfiles of Leading Medical OrganizationsCedars-SinaiEmory HealthcareGeisinger Health SystemsIntermountain HealthcareKaiser PermanenteMayo ClinicMD Anderson Cancer CenterMoffitt Cancer CenterMount Sinai Health SystemNationwide Children's HospitalPartners HealthCareSanford HealthSt. Jude Children's HospitalVanderbilt University Medical Center 4. MEDICAL INDUSTRY CHALLENGES Clinical Genomics - Unmet Needs and ChallengesTechnical Challenges Associated with Scaling Clinical Genomics ApplicationsScientific Challenges Associated with the Implementation of Clinical GenomicsNon-Technical / Scientific Challenges Associated with the Implementation of Clinical Genomics Applications 5. GENOMIC DATA GENERATION, DATA FLOW, AND DATA WAREHOUSING Rethinking Optimized Genomic Data Generation and Data FlowStructures of Successful Big Data PlatformsScalable Data Generation and Data Flow Lacking Data StandardsSlow Integration of Clinical Genomics Data with Other Clinical/Patient DataCurrent EMR/EHR Systems Do Not Support Genomics DataVariant Data Warehousing for Data Analysis, Mining, and QueryingEnterprise Data Platform ArchitectureIntegration of Various Types of DataA Data Warehouse That Supports Clinical ResearchData Warehousing and Fast Data Processing Requires a Scalable InfrastructureThe Ideal Variant Data Analysis and Query PlatformData Warehouse versus a Data LakeCloud Is the Preferred Infrastructure 6. CLINICAL GENOMICS DATA SOLUTIONS Genomic Data Infrastructures/Platforms for Data Storage, Processing, and AnalysisScaled Data Storage and Computing SolutionsClinical Genomics Data PlatformsIntegrated Genomic WorkflowData Processing Speed, Scalability, and FlexibilityClinical Data Management & Knowledge ExtractionClinico-Genomic Data Management and IntegrationGenomic/Variant Data Querying and AnalysisVariant Data Interpretation/Decision Making/ReportingTertiary Analysis - Sequence Data Interpretation and Insight GenerationTertiary Analysis - Embedded Interpretation Content for Insight GenerationData Processing, Knowledge Extraction, and Reporting Companies Side-by-Side 7. CLINICAL GENOMICS MARKET TRENDS Factors Impacting Clinical Sequencing AdoptionGenetic Testing and Molecular Profiling TrendsThe Increasing Trend of Clinical Genetic TestingClinical Genomics Applications to Be Established in the Clinic as a RoutineRoutine Genomic Applications Established over the Next Three to Five YearsRequirements to Establish Genomic Applications as a RoutineMergers, Acquisitions, and Partnerships Accelerate Adoption of Clinical GenomicsAgilent Is Building Integrated, Complete Clinical Workflow SolutionsIllumina's M&As Suggest the Goal of a Fully Integrated Sequencing SolutionRoche Is Expanding its Diagnostics BusinessThermo Fisher Scientific Is Strengthening Its Presence in the Clinical SectorQIAGEN Is Pushing the Molecular Diagnostics and Clinical Research MarketsOther Acquisitions and Partnerships 8. TECHNOLOGIES IMPACTING THE IMPLEMENTATION OF CLINICAL GENOMICS & MOLECULAR PROFILING APPLICATIONS 3rd and 4th Generation Sequencing TechnologyArtificial Intelligence/Machine Learning ApplicationsAI in Healthcare Adoption DriversLiquid Biopsy in Clinical DiagnosticsLiquid Biopsy Clinical ApplicationsLong-Read Sequencing TechnologyReal-World Data / Real-World EvidenceThe FDA Is Attempting to Define RWD and RWEAn Uptick of RWD and RWE PublicationsThe Benefits of Real-World EvidenceThe Challenges of Using RWD and RWEAn Active Playing Field of Commercial RWD PlayersClinical Genomics Adoption Challenges 9. COVID-19, THE HEALTHCARE DISRUPTER Diagnostics - Commercial Companies RevampingDiagnostics Companies Quickly PivotedCOVID-19, a Disrupter, but also an OpportunityViral Sequencing Reveals How SARSCo-V-2 Evolves and SpreadsCOVID-19 Resulted in Unprecedented Data SharingCOVID-19 and the Massive Disruptions to Clinical Trials Processes 10. COMMERCIAL CLINICAL SOLUTIONS / PRODUCT PROVIDERS Company ProfilesBC PlatformsBluebee (an Illumina company)ColorCongenicaDNAnexusFabric GenomicsFoundation MedicineFreenomeGenooxGenuity ScienceGoogle Life SciencesGRAILHelixIlluminaInvitaePierianDxQIAGENSeven BridgesSOPHiA GeneticsTempus 11. THE FUNDING SITUATION 12. APPENDIX Clinical Genomics End User TypesThe Computational Scientist/BioinformaticianThe Data ScientistThe Non-Computational CollaboratorThe Genetic CounselorThe Clinical GeneticistThe PhysicianThe Patient 13. ABBREVIATIONSFor more information about this report visit https://www.researchandmarkets.com/r/hfqr98 CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

  • Jennifer Aniston Adoption Rumours Dismissed By Spokesperson

    Reports claimed the actor told her Friends co-stars of her plans to adopt a baby girl during filming of the reunion special last week.

  • Matt Willis alleges that Scientologists tried to ‘split up’ his marriage

    Former Busted musician was briefly involved with the Church following a 2008 rehab stint

  • Retired couple scoop EuroMillions win after husband forgets his glasses while buying ticket

    Denis and Ann Fawsitt won over £100,000 as a result of a lucky bout of forgetfulness.

  • We tried every product from the new e.l.f. XX Jen Atkin make-up collection – here’s our verdict

    Starting from just £5, is the budget-friendly range a hit or miss?

  • Credit Suisse Sells $2 Billion of Archegos-Linked Stocks

    (Bloomberg) -- Credit Suisse Group AG unloaded about $2 billion of stocks tied to the Archegos Capital Management blowup in the second such block sale since the bank wrote down the bulk of its exposure in the first quarter.The stock offerings included Discovery Inc. and Iqiyi Inc., adding to some $2.3 billion worth of shares tied to the debacle that the bank sold last week, according to people familiar with the matter. The trades follow a torrent of similar transactions that had already erased about $194 billion in market value as banks from New York to Zurich and Tokyo unwound leveraged equity bets by Bill Hwang’s family office.Shares of Credit Suisse fell as the sale adds to evidence that the Archegos collapse could impact the bank beyond the first quarter, when it took a 4.4 billion franc ($4.8 billion) writedown, its worst trading hit in more than a decade. While the Swiss bank has substantially reduced its exposure, transactions since the end of March weren’t included in the first-quarter results, a person familiar with the matter has said.Credit Suisse fell as much as 2.2% in early Zurich trading and was 1.2% lower by 9:43 a.m. The stock has lost 15% this year, compared with double-digit gains for an index that includes its European peers.A spokesperson for Credit Suisse declined to comment on the sale and whether the bank plans more such transactions.Hwang’s private investment firm became the center of one of the biggest margin calls of all time late last month, and represented one of the most spectacular failures of risk-management and oversight in recent memory. The downfall of Archegos will result in $10 billion of losses to banks, according to analysts at JPMorgan Chase & Co. The debacle could attract regulatory scrutiny and potential fines for the banks involved, the analysts said this week.Read more: Archegos Ripples Through Banks’ Lucrative Hedge Fund BusinessTuesday’s block trades -- which sold at the lower end of ranges -- included 19 million Class A shares of Discovery sold at $38.40, said one of the people, asking not to be identified discussing a private matter. In addition, 22 million Class C shares of Discovery sold at $32.35 while a stake of 35 million Iqiyi shares went for $15.85.Credit Suisse’s latest sale comes weeks after several rivals dumped their shares to skirt losses. While the firm was one of several global investment banks to facilitate the leveraged bets of Archegos, it was slower than others to unwind the positions and had initially tried to reach some sort of standstill agreement, people familiar with the matter have said.The strategy failed as rivals rushed to cut their losses. Global banks including Goldman Sachs Group Inc. and Deutsche Bank AG have told investors that they shed their Archegos-linked positions with little financial impact.Credit Suisse is now planning a sweeping overhaul of its hedge fund business. It has already announced plans to cut its dividend, suspend share buybacks and scrap bonuses for top executives.(Updates with Credit Suisse shares from third paragraph.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.

  • Clinical Trial Packaging and Labelling Market Forecast 2020-2030

    Revenue Prospects by Type (Primary Packaging (Blisters, Bottles, Pouches, Tubes, Others), Secondary Packaging (Labelling for Parenteral and Injectable, Just in Time Labelling, Tyvek Blistering for Parenteral, Cartons, Others)), End Users (Drug Manufacturing Companies, Research Labs and CROs), Profiles of Leading Companies and Regional and Leading National Market Analysis.New York, April 14, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Clinical Trial Packaging and Labelling Market Forecast 2020-2030" - https://www.reportlinker.com/p06058481/?utm_source=GNW Clinical Trial Packaging and Labelling- our new study reveals trends, R&D progress, and predicted revenues Where is the Clinical Trial Packaging and Labelling market heading? If you are involved in this sector you must read this newly updated report. This report shows you the potential revenues streams to 2030, assessing data, trends, opportunities and business prospects there. Discover how to stay ahead Our 171 pages report provides 96 tables, 50 charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Clinical Trial Packaging and Labelling Market. See how to exploit the opportunities. Forecasts to 2030 and other analyses reveal the commercial prospects • In addition to revenue forecasting to 2030, our new study provides you with recent results, growth rates, and market shares. • You find original analyses, with business outlooks and developments. • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments. Discover sales predictions for the world market and submarkets Along with revenue prediction for the overall world market, there are following segments, each forecasted at a global and regional level. Clinical Trial Packaging and Labelling Market by Type Primary Packaging • Blisters • Bottles • Pouches • Tubes • Others Secondary Packaging • Labelling for Parenteral and Injectable • Just in Time Labelling • Tyvek Blistering for Parenteral • Cartons • Others Clinical Trial Packaging and Labelling Market by End Users • CRO’s • Drug Manufacturing Companies • Research Labs In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 17 leading national markets: North America • U.S. • Canada • Latin America: • Brazil • Mexico • Rest of Latin America Europe (EU) • Germany • France • UK • Italy • Spain • Rest of Europe Asia-Pacific (APAC) • Japan • China • India • Australia • ASEAN • Rest of Asia-Pacific Middle East and Africa (MEA) • GCC Countries • South Africa • Rest of MEA Leading companies and the potential for market growth Overall world revenue for Clinical Trial Packaging and Labelling Market will surpass $900 million in 2020, our work calculates. We predict strong revenue growth through to 2030. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead. How the Clinical Trial Packaging and Labelling Market report helps you In summary, our 181 pages report provides you with the following knowledge: • Revenue forecasts to 2030 for 5 regional and 17 key national markets- See forecasts for the Clinical Trial Packaging and Labelling market in North America, Latin America, Europe, Asia-Pacific and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, Spain, China, India, Japan, Australia, ASEAN countries, GCC Countries and South Africa. • Prospects for established firms and those seeking to enter the market- including company profiles for 13 of the major companies involved in the Clinical Trial Packaging and Labelling market Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence. Information found nowhere else With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. This study is for everybody needing commercial analyses for the Clinical Trial Packaging and Labelling market and leading companies. You will find data, trends and predictions.Read the full report: https://www.reportlinker.com/p06058481/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

  • Shirley Williams: One of the UK’s best-loved politicians

    Readily known by her first name, Shirley Williams, once tipped to become the first female prime minister, enhanced the quality of public life

  • John Kerry visits China on climate mission ahead of US summit

    Envoy says global warming ‘must stand alone’ in great power relations, despite disagreements elsewhere

  • Global Asphalt Pavers Market Report 2020-2027: Market Size is Expected to Reach $1,410.03 Million - Strong Government Funding & Introduction of New Technologies

    Dublin, April 14, 2021 (GLOBE NEWSWIRE) -- The "Asphalt Pavers Market Share, Size, Trends, Industry Analysis Report, By Product Type; By Screed Type; By Operating Weight; By Paving Width; By Regions; Segment Forecast, 2020-2027" report has been added to ResearchAndMarkets.com's offering. The global asphalt pavers market size is expected to reach USD 1,410.03 million by 2027China is focusing on the development of its western region. In line with this, it has announced various infrastructure projects for the Tibet region as well. India is mainly focusing on the development of its transport network by investing heavily in road and rail infrastructure. Furthermore, the country is focusing on improving power infrastructure by building thermal, nuclear, wind, and solar power stations.Traffic has grown by 150 times over the last 50 years, while roads have increased by 9 times during the same period. The quality of roads in India is quite poor, leading to annual economic losses of US$ 4 Bn to US$ 7 Bn. The Indian construction equipment market has the potential to grow up to significantly, owing to the government's focus on infrastructure developments.Intelligent pavement refers to the pavement of asphalt using asphalt pavers equipped with global positioning systems (GPS) based mapping sensors and optional feedback controls. It is one of the most important progress made in roadway construction and has been widely adopted by Europe and China's manufacturers.In order to meet the changing need of the European market coupled with increasing demand for higher levels of operator comfort and safety. Despite their smaller dimensions, manufacturers are continuing to improve the operator's working environment by adding more comfort and safety features to their machines. For instance, Hamm's newly launched Asphalt Pavers enhance maximum possible operators' comfort, exceptionally good visibility, and the highest possible operational safety.Market participants such as Caterpillar, Sunroc Corporation, Astec Industry, Gencor Industries, Inc., Wirtgen group, Volvo CE, Ammann, Sumitomo, Fayat Group, Sany, Zoomlion, VT Leeboy, Shantui, and XCMG are some of the key players operating in the global market. Market players are focusing on mergers, acquisitions, technological advancements to have a competitive edge in the market. For instance, in July 2020, Gencor Industries announced a definitive agreement to acquire paver business from Blaw Knox, the Pennsylvania, U.S. based paver equipment manufacturer. Key Topics Covered: 1. Introduction2. Executive Summary3. Research Methodology3.1. Overview3.2. Data Sources4. Asphalt Pavers Market Insights4.1. Asphalt Pavers - Industry snapshot4.2. Asphalt Pavers Market Dynamics4.2.1. Drivers and Opportunities4.2.1.1. Strong government funding4.2.1.2. Introduction of new technologies4.2.2. Restraints and Challenges4.2.2.1. Cost escalations4.3. Porter's Five Forces Analysis4.4. PESTLE Analysis4.4.1. Asphalt Pavers Market Industry trends5. Asphalt Pavers Market Assessment by Product Type5.1. Key Findings5.2. Introduction5.3. Tracked Pavers5.4. Wheeled Pavers6. Global Asphalt Pavers Market, by Screed Type6.1. Key Findings6.2. Introduction6.3. Hydrostatic6.4. Mechanical7. Global Asphalt Pavers Market, by Operating Weight7.1. Key Findings7.2. Introduction7.3. 5000-8000 Kgs7.4. 8000-12000 Kgs7.5. 12000-15000 Kgs7.6. Over 15000 Kgs8. Asphalt Pavers Market Assessment by Paving Width8.1. Key Findings8.2. Introduction8.3. Up to 1.5 m8.4. 1.5-2.5 m8.5. 2.5-5 m8.6. Over 5 m9. Asphalt Pavers Market Assessment by Geography9.1. Key findings9.2. Introduction9.2.1. Asphalt Pavers Market Assessment, By Geography, 2016-2027 (USD Million)10. Competitive Landscape10.1. Expansion and Acquisition Analysis10.1.1. Expansion10.1.2. Acquisitions10.2. Partnerships/Collaborations/Agreements/Exhibitions11. Company Profiles11.1. Company Overview11.2. Financial Performance11.3. Product Benchmarking11.4. Recent Developments CaterpillarAstec IndustryWirtgen groupVolvo CEAmmannSumitomoFayat GroupSanyZoomlionVT LeeboyShantuiXCMG For more information about this report visit https://www.researchandmarkets.com/r/nmqivk CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

  • IEA ups oil demand forecast as vaccinations brighten outlook

    Vaccine rollouts are brightening the outlook for global oil demand, the International Energy Agency (IEA) said on Wednesday, though rising cases in some major oil-consuming countries show a recovery may be fragile. "Fundamentals look decidedly stronger," the IEA said in its monthly report. "The massive overhang in global oil inventories that built up during last year's COVID-19 demand shock is being worked off, vaccine campaigns are gathering pace and the global economy appears to be on a better footing."

  • EU parliament again refuses to set date for ratifying Brexit trade deal amid concerns over UK conduct

    Senior MEP says ‘cool heads must prevail’ in holding UK to commitments

  • IEA: Goodbye oil glut thanks to OPEC+ and recovery

    A glut in global oil markets is being worked off as the world economy begins to recover from the Covid-19 pandemic and as OPEC and its allies restrain production, the IEA said Wednesday.

  • Scrabble bans racial slurs causing some to boycott family board game

    Three prominent members of the global Scrabble players’ organisation quit in response to the changes